- Innocan Pharma Corp. (INNO) shares results from a study using its CBD- Loaded Liposome Platform Technology (LPT) delivery system
- Cannabidiol (CBD) remained present in mice’s brains 41 days after being injected with Innocan’s CBD LPT
- Prolonged and controlled release of CBD from the delivery system injected subcutaneously showed relevant concentrations of CBD remained in the blood for a long time
- The pharmacokinetics of the system may achieve controlled concentrations of CBD in blood leading to a better clinical outcome
- Innocan Pharma Corp. (INNO) is down 2.56 per cent and is trading at $0.76 per share at 3:59 p.m. ET
Innocan Pharma Corp. (INNO) shows results from a study using its CBD-Loaded Liposome Platform Technology (LPT) delivery system.
Cannabidiol (CBD) remained present in mice’s brains 41 days after being injected with Innocan’s CBD LPT.
However, no CBD showed up in the mice’s brains 22 days following the injection of free CBD (without using Innocan’s LPT delivery system).
Prolonged and controlled release of CBD from the delivery system injected subcutaneously showed continuous relevant concentrations of CBD in the blood for a long time.
Innocan believes this will be a good predictor of CBD exposure when administered to humans.
It also thinks that the continuous and long blood of CBD for a longer time post local administration seems to be superior to orally administered CBD for two reasons.
First, it will allow a single administration of CBD instead of daily administration and will overcome the low oral bioavailability of CBD which is around 10 to 20 per cent.
The pharmacokinetics of the system administered may achieve controlled concentrations of CBD in the blood leading to a better clinical outcome.
Professor Chezy Barenholz of The Hebrew University of Jerusalem said this is another step-up in the research by showing measurable evidence to the relative bioavailability of CBD once using the LPT delivery system.
Iris Bincovish, CEO of Innocan, added, “Our nexus between deep scientific expertise and robust pharma commercialization know-how is, once again, showing its results.”
“We hope that such valuable breakthroughs will help in positioning Innocan as a substantial player in the CBD pharma industry,” he said.
Innocan Pharma Corp. (INNO) is down 2.56 per cent and is trading at $0.76 per share at 3:59 p.m. ET.
